Related Experiment Video
Updated: May 7, 2026
07:21
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
Does immunohistochemistry provide additional prognostic data in gastrointestinal stromal tumors?
Lutfiye Demir1, Nese Ekinci, Cigdem Erten
1Department of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University, Turkey
Asian Pacific Journal of Cancer Prevention : APJCP
|October 3, 2013
Summary
Mitotic activity is the strongest prognostic factor for gastrointestinal stromal tumors (GISTs). While high Ki-67 and CD34 expression negatively impact prognosis, SMA positivity appears beneficial for GIST patient survival.
Area of Science:
- Oncology
- Gastrointestinal Pathology
Background:
- Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract.
- Understanding prognostic factors is crucial for patient management and treatment strategies.
Purpose of the Study:
- To investigate the predictive and prognostic effects of clinicopathologic and immunohistochemical (IHC) features in patients with GISTs.
- To identify key factors influencing overall survival (OS) and disease-free survival (DFS) in GIST patients.
Main Methods:
- Retrospective evaluation of 56 GIST patients diagnosed between 2002 and 2012.
- Analysis of relationships between clinicopathologic/immunohistochemical factors and patient prognosis.
Main Results:
- Mitotic activity (≥10/50HPF) was the sole independent predictor of mortality in GIST patients.
- Epithelioid morphology and high Ki-67 levels (≥30%) were associated with significantly shortened OS.
- SMA positivity correlated with lower mitotic activity, longer OS, and improved DFS, while CD34 negativity was linked to longer progression-free survival (PFS).
Conclusions:
- Mitotic activity remains the most significant prognostic factor for GISTs, despite negative impacts of high Ki-67 and CD34 expression.
- SMA positivity may have a positive prognostic influence in GIST patients.
- Further large-scale, multicenter studies are needed to validate these findings.